NOS1AP基因多态性对瑞舒伐他汀钙调脂效果的影响Δ

发布时间：2018-12-08 20:06

【摘要】：目的:探讨一氧化氮合酶1转接蛋白(NOS1AP)基因rsl2742393位点A/C多态性对瑞舒伐他汀钙调脂效果的影响。方法:选取2014年1月-2015年6月于我院心内科接受治疗的冠心病患者236例,予瑞舒伐他汀钙等对症治疗12周。采用聚合酶链反应-限制性片段长度多态性分析法检测各患者NOS1AP基因rs12742393位点A/C多态性,采用光电比色法分别于治疗前和治疗后第4、12周检测其血清三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)水平,分析患者基因型与血脂水平变化的相关性。结果:236例冠心病患者中,AA、AC、CC基因型分别有131(55.5%)、98(41.5%)和7例(3.0%),各基因型和等位基因频率均符合Hardy-Weinberg平衡(P0.05);血脂正常患者132例,合并高脂血症患者104例,两者各基因型和等位基因型频率比较,差异均有统计学意义(P0.05)。104例冠心病合并高脂血症患者在治疗前,AA与AC+CC基因型患者TG、TC、LDL-C和HDL-C水平比较,差异均无统计学意义(P0.05)。治疗后第4、12周,各基因型患者TG、TC和LDL-C水平均较治疗前显著降低;治疗后第4周,AC+CC基因型患者LDL-C水平显著低于AA基因型患者,且较治疗前的变化幅度显著大于AA基因型患者,差异均有统计学意义(P0.05);各基因型患者HDL-C水平与治疗前比较,治疗后第4、12周AA基因型患者TG、TC、HLD-C水平及其较治疗前的变化幅度与AC+CC基因型患者比较,以及治疗后第12周AA基因型患者LDL-C水平及其较治疗前的变化幅度与AC+CC基因型患者比较,差异均无统计学意义(P0.05)。结论:NOS1AP基因rs12742393位点A/C多态性与冠心病患者合并高脂血症有关,该位点C等位基因可能通过影响LDL-C水平来增强冠心病合并高脂血症患者对瑞舒伐他汀钙调脂效果的反应性。
[Abstract]:Aim: to investigate the effect of rsl2742393 polymorphism of nitric oxide synthase 1 (NOS1AP) gene on the effect of rosuvastatin calmodulin. Methods: 236 patients with coronary heart disease who were treated in our hospital from January 2014 to June 2015 were treated with recuvastatin calcium for 12 weeks. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to detect the rs12742393 locus A / C polymorphism of NOS1AP gene in each patient. The serum triglyceride (TG), was detected by photoelectric colorimetry before treatment and 412 weeks after treatment. The levels of total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C) were analyzed. Results: the AA,AC,CC genotypes were 131 (55.5%), 98 (41.5%) and 7 (3.0%) in 236 patients with coronary heart disease, respectively. The frequencies of each genotype and allele were in line with Hardy-Weinberg balance (P0.05). 132 patients with normal blood lipid and 104 patients with hyperlipidemia were compared with each genotype and allele frequency (P0.05). 104 patients with coronary heart disease complicated with hyperlipidemia before treatment, There was no significant difference in TG,TC,LDL-C and HDL-C levels between AA and AC CC genotype patients (P0.05). At the 12th week after treatment, the levels of TG,TC and LDL-C in all genotypes were significantly lower than those before treatment. The level of LDL-C in patients with, AC CC genotype was significantly lower than that in patients with AA genotype at the 4th week after treatment, and the change was significantly larger than that in patients with AA genotype before treatment (P0.05). The levels of HDL-C in patients with different genotypes were compared with those before treatment, and the TG,TC,HLD-C levels in patients with AA genotype at the 4th week after treatment were compared with those in patients with AC CC genotypes at the 4th week after treatment. There was no significant difference in the level of LDL-C and the change of LDL-C between the patients with AA genotype and the patients with AC CC genotype at the 12th week after treatment (P0.05). Conclusion: the rs12742393 polymorphism of NOS1AP gene is associated with hyperlipidemia in patients with coronary heart disease. The C allele may influence the LDL-C level to enhance the response of patients with coronary heart disease with hyperlipidemia to rosuvastatin calmodulating effect.
【作者单位】：无锡市第三人民医院药学部;无锡市第三人民医院心内科;
【分类号】：R969.3

【相似文献】